SCHEMBL3727261

SCHEMBL3727261

C=CC1C(=O)N(c2ccccc2)N=C1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOX P28300 1/20 0.61
▸ LOXL3 P58215 1/20 0.61
▸ LOXL4 Q96JB6 1/20 0.61
▸ LOXL2 Q9Y4K0 1/20 0.61
▸ MAPT P10636 10/20 0.60
▸ ALDH1A1 P00352 7/20 0.60
▸ MEN1 O00255 5/20 0.60
▸ KMT2A Q03164 5/20 0.60
▸ KDM4E B2RXH2 5/20 0.60
▸ PSMD14 O00487 1/20 0.60
▸ NSD2 O96028 1/20 0.60
▸ DNMT1 P26358 1/20 0.60
▸ RXFP1 Q9HBX9 1/20 0.60
▸ GFER P55789 2/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ THRB P10828 1/20 0.55
▸ CES2 O00748 4/20 0.54
▸ LMNA P02545 3/20 0.52
▸ HTT P42858 2/20 0.52
▸ PKM P14618 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5713339 0.85 LOX (0.63) LOXLOXL3LOXL4LOXL2MAPT
SCHEMBL22922974 0.80 CES2 (0.68) LOXLOXL3LOXL4LOXL2MAPT
SCHEMBL968992 0.79 MEN1 (0.59) LOXLOXL3LOXL4LOXL2MAPT
SCHEMBL186331 0.78 LOX (0.71) LOXLOXL3LOXL4LOXL2MAPT
SCHEMBL305089 0.77 MAPT (0.61) LOXLOXL3LOXL4LOXL2MAPT
SCHEMBL10078302 0.77 MAPT (0.61) LOXLOXL3LOXL4LOXL2MAPT
SCHEMBL247053 0.77 MAPT (0.61) LOXLOXL3LOXL4LOXL2MAPT
SCHEMBL1086022 0.76 LOX (1.00) LOXLOXL3LOXL4LOXL2MAPT
SCHEMBL8992445 0.76 LOX (0.55) LOXLOXL3LOXL4LOXL2MAPT
SCHEMBL12766787 0.75 LOX (0.67) LOXLOXL3LOXL4LOXL2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4425628-B2 — — 2010-03-03 — — JP claimed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 — — EP claimed
JP-2005505519-A — — 2005-02-24 — — JP claimed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 — — EP claimed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 — — US claimed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 — — WO claimed
US-7629375-B2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2009-12-08 — — US disclosed
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2006-08-10 — — US disclosed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 — — EP disclosed
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER INC. 2005-06-30 — — US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 — — US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 — — EP disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 — — US disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 LOX 163/4885LOXL3 371/4885LOXL4 431/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 LOX 163/4885LOXL3 371/4885LOXL4 431/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 LOX 163/4885LOXL3 371/4885LOXL4 431/4885
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 LOX 163/4885LOXL3 371/4885LOXL4 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback